Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833341 | 0.89 | LIPG (0.45) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL18015286 | 0.88 | LPL (0.44) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL29771558 | 0.88 | LPL (0.44) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL29327579 | 0.86 | LPL (0.40) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL19933716 | 0.85 | LPL (0.41) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL19544227 | 0.83 | LPL (0.47) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL19106491 | 0.81 | LIPG (0.51) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL20696470 | 0.81 | DGAT1 (0.43) | LPLLIPGPDK2DGAT1PDGFRB | |
| SCHEMBL18015380 | 0.81 | PDK2 (0.45) | PDK2WNT3ANPC1PKMRAB9A | |
| SCHEMBL20696492 | 0.81 | DGAT1 (0.47) | LPLLIPGPDK2DGAT1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | LPL 4682/4885LIPG 4459/4885PDK2 3655/4885 |
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | LPL 3716/4885LIPG 3983/4885PDK2 2960/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | LPL 3416/4885LIPG 3693/4885PDK2 2111/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | LPL 3716/4885LIPG 3983/4885PDK2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.